🇺🇸 FDA
Pipeline program

Dupilumab

EFC18366

Phase 3 small_molecule active

Quick answer

Dupilumab for Lichen Simplex Chronicus is a Phase 3 program (small_molecule) at REGENERON PHARMACEUTICALS, INC. with 2 ClinicalTrials.gov record(s).

Program details

Company
REGENERON PHARMACEUTICALS, INC.
Indication
Lichen Simplex Chronicus
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials